Cyclacel Pharmaceuticals Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St set to open lower as oil, bond yields tick up
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
Cyclacel Pharma (CYCC) Tops Q1 EPS by 8c
May 14, 2019 4:21 PM EDTCyclacel Pharma (NASDAQ: CYCC) reported Q1 EPS of ($0.12), $0.08 better than the analyst estimate of ($0.20).
We continue to execute on our strategy to develop innovative therapies to overcome cancer resistance mechanisms through combinations of our candidates with approved drugs, said Spiro Rombotis, President and Chief... More
